Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT

Pfizer logo

Pfizer

Status and phase

Completed
Phase 4

Conditions

Hypertension

Treatments

Drug: Eplerenone

Study type

Interventional

Funder types

Industry

Identifiers

NCT00147563
EPLA-0501-077
A6141016

Details and patient eligibility

About

To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blood pressure control achieved with a b-blocker, atenolol.

Sex

All

Ages

30 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Pt with essential hypertension who have never been treated or untreated within the previous 6 months

Exclusion criteria

  • History of Malignant Hypertension
  • Sitting diastolic blood pressure > 115mmHg or sitting Systolic blood pressure > 200mmHg

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems